Abstract:This narrative review focuses on the role of cholesteryl ester transfer protein (CETP) and peripheral lipoproteins in the vascular contributions to cognitive impairment and dementia (VCID). Humans have a peripheral lipoprotein profile where low-density lipoproteins (LDL) represent the dominant lipoprotein fraction and high-density lipoproteins (HDL) represent a minor lipoprotein fraction. Elevated LDL-cholesterol (LDL-C) levels are well-established to cause cardiovascular disease and several LDL-C-lowering therapies are clinically available to manage this vascular risk factor. The efficacy of LDL-C-lowering therapies to reduce risk of all-cause dementia and AD is now important to address as recent studies demonstrate a role for LDL in Alzheimer's Disease (AD) as well as in all-cause dementia. The LDL:HDL ratio in humans is set mainly by CETP activity, which exchanges cholesteryl esters for triglycerides across lipoprotein fractions to raise LDL and lower HDL as CETP activity increases. Genetic and pharmacological studies support the hypothesis that CETP inhibition reduces cardiovascular risk by lowering LDL, which, by extension, may also lower VCID. Unlike humans, wild-type mice do not express catalytically active CETP and have HDL as their major lipoprotein fraction. As HDL has potent beneficial effects on endothelial cells, the naturally high HDL levels in mice protect them from vascular disorders, likely including VCID. Genetic restoration of CETP expression in mice to generate a more human-like lipid profile may increase the relevance of murine models for VCID studies. The therapeutic potential of existing and emerging LDL-lowering therapies for VCID will be discussed. Figure Legend. Cholesteryl Ester Transfer Protein in Alzheimer's Disease. CETP is mainly produced by the liver, and exchanges cholesteryl esters for triglycerides across lipoprotein fractions to raise circulating LDL and lower HDL as CETP activity increases. Low CETP activity is associated with better cardiovascular health, due to decreased LDL and increased HDL, which may also improve brain health. Although most peripheral lipoproteins cannot enter the brain parenchyma due to the BBB, it is increasingly appreciated that direct access to the vascular endothelium may enable peripheral lipoproteins to have indirect effects on brain health. Thus, lipoproteins may affect the cerebrovasculature from both sides of the BBB. Recent studies show an association between elevated plasma LDL, a well-known cardiovascular risk factor, and a higher risk of AD, and considerable evidence suggests that high HDL levels are associated with reduced CAA and lower neuroinflammation. Considering the potential detrimental role of LDL in AD and the importance of HDL's beneficial effects on endothelial cells, high CETP activity may lead to compromised BBB integrity, increased CAA deposits and greater neuroinflammation. Abbreviations: CETP - cholesteryl transfer ester protein; LDL - low-density lipoproteins; HDL - high-density lipoproteins; BBB - blood-brain barrier; CAA - cerebral amyloid angiopathy, SMC - smooth muscle cells, PVM - perivascular macrophages, RBC - red blood cells.

Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update

Cholesteryl Ester Transfer Protein Concentrations in Subjects with Various Dyslipidaemias

Cholesteryl ester transfer protein gene variation relate to lipid parameters and cardiovascular risk

Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity

The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis D.M. is supported by a grant from the Philippe Foundation. Published, JLR Papers in Press, November 20, 2008.

The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease

Cholesteryl Ester Transfer Protein Activity and Cardiovascular Events in Patients with Chronic Kidney Disease Stage V

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults

Cholesteryl Ester Transfer Protein (CETP) Expression Enhances HDL Cholesteryl Ester Liver Delivery, Which is Independent of Scavenger Receptor BI, LDL Receptor Related Protein and Possibly LDL Receptor

CETP and oxidized LDL levels increase in dyslipidemic subjects.

Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia

The Lipid Transfer Properties of CETP Define the Concentration and Composition of Plasma Lipoproteins.

Variants in the CETP gene affect levels of HDL cholesterol by reducing the amount, and not the specific lipid transfer activity, of secreted CETP

Abstract 1025: Importance of Macrophage Cholesteryl Ester Transfer Protein (CETP) for Determining Serum Cholesteryl Ester Transfer Activity and Atherosclerosis

Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice

4P-1030 Diplotype analysis identified lower expression haplotype of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism

Both full length-cholesteryl ester transfer protein and exon 9-deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes

Common Genetic Variation of the Cholesteryl Ester Transfer Protein Gene Strongly Predicts Future Cardiovascular Death in Patients with Coronary Artery Disease

Comparative Studies of Three Cholesteryl Ester Transfer Proteins and Their Interactions with Known Inhibitors

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin